Argenx
ARGX
#440
Rank
A$82.79 B
Marketcap
A$1,325
Share price
0.34%
Change (1 day)
57.86%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.77. In 2025 the company made an earnings per share (EPS) of A$30.36 an increase over its 2024 EPS that were of A$20.05.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-22.06%
2025A$30.3651.44%
2024A$20.05-369.77%
2023A-$7.43-60.46%
2022A-$18.7963.33%
2021A-$11.51-40.37%
2020A-$19.30183.47%
2019A-$6.81123.09%
2018A-$3.0554.93%
2017A-$1.9714.07%
2016A-$1.7313.05%
2015A-$1.53-36.34%
2014A-$2.40209.04%
2013A-$0.78-33.99%
2012A-$1.18185.59%
2011A-$0.41